Novavax (NVAX) Tops Q2 EPS by 68c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Price: $7.96 --0%
Financial Fact:
Basic and diluted net loss per share: -0.24
Today's EPS Names:
VAXX, NMRD, EGRX, More
Financial Fact:
Basic and diluted net loss per share: -0.24
Today's EPS Names:
VAXX, NMRD, EGRX, More
Join SI Premium – FREE
Novavax (NASDAQ: NVAX) reported Q2 EPS of $0.62, $0.68 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $239 million versus the consensus estimate of $156.23 million.
GUIDANCE:
Novavax sees Q3 2025 revenue of $495-545 million, versus the consensus of $89.61 million.
Novavax sees FY2025 revenue of $1-1.05 billion, versus the consensus of $1.02 billion.
For earnings history and earnings-related data on Novavax (NVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
- CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance
- Stratasys (SSYS) Tops Q2 EPS by 2c ;; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
